Literature DB >> 2715367

Propafenone disposition in renal insufficiency and renal failure.

E Burgess1, H Duff, P Wilkes.   

Abstract

The pharmacokinetics of a single intravenous dose of propafenone were studied in subjects with normal renal function (n = 5), renal insufficiency (n = 5), and renal failure (n = 3). No difference in central volume of distribution, total ischemic clearance or terminal half-life existed. None of the pharmacokinetic parameters examined correlated to creatinine clearance. Within the confines of the small number of patients studied, there does not appear to be any effect of renal insufficiency or failure on single-dose propafenone disposition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715367     DOI: 10.1002/j.1552-4604.1989.tb03296.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

4.  Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites.

Authors:  M F Fromm; S Botsch; G Heinkele; J Evers; H K Kroemer
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Authors:  K Yoshida; B Sun; L Zhang; P Zhao; D R Abernethy; T D Nolin; A Rostami-Hodjegan; I Zineh; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2016-03-07       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.